Welcome to our dedicated page for GMDA news (Ticker: GMDA), a resource for investors and traders seeking the latest updates and insights on GMDA stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect GMDA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of GMDA's position in the market.
Gamida Cell Ltd. (Nasdaq: GMDA) has expanded its strategic collaboration with Be The Match BioTherapies to enhance the supply chain for its advanced cell therapy, omidubicel. This partnership aims to improve patient access to hematopoietic stem cell transplants, which are crucial for blood cancer treatments. Omidubicel, now in Phase 3 clinical development, has shown promising results in reducing time to neutrophil engraftment. The collaboration signifies a step towards potential FDA approval and aims to address the gap where over 40% of eligible patients do not receive transplants due to donor matching issues.
Gamida Cell Ltd. (Nasdaq: GMDA) announced that Michele Korfin, the chief operating and commercial officer, will present at the 2020 Virtual Cell & Gene Meeting on the Mesa. The conference takes place from October 12 to October 16, with company presentations available on-demand throughout the event. Gamida Cell focuses on advanced cell therapies aimed at curing blood cancers and serious blood diseases. Complimentary attendance is available for credentialed investors and media. For more details, visit www.meetingonthemesa.com.
Gamida Cell (Nasdaq: GMDA) announced that its Phase 3 study of omidubicel, an advanced cell therapy for blood cancers, successfully met all three secondary endpoints. Omidubicel aims to provide an effective alternative for patients needing a bone marrow transplant, particularly for those without a matched donor. Key results included significant improvements in platelet engraftment and reduced infections. The company plans to submit a biologics license application to the FDA and present full data at a medical meeting in Q4 2020.